Scott J Diede

List of Publications by Year
in descending order

35 papers	2,941 citations	304743 22 h-index	361022 35 g-index
36 all docs	36 docs citations	36 times ranked	4863 citing authors

#	Article	IF	Citations
1	KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. European Journal of Cancer, 2022, 160, 1-11.	2.8	4
2	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. European Journal of Cancer, 2021, 144, 182-191.	2.8	57
3	Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-oncology Clinical Trials. JAMA Network Open, 2021, 4, e218175.	5.9	13
4	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. European Journal of Cancer, 2021, 157, 391-402.	2.8	13
5	Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers. Journal of Medical Economics, 2020, 23, 132-138.	2.1	6
6	Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1â€“2 trial. Lancet Oncology, The, 2020, 21, 121-133.	10.7	204
7	Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings. Quality of Life Research, 2020, 29, 2651-2660.	3.1	17
8	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. European Journal of Cancer, 2020, 127, 52-66.	2.8	52
9	KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. , 2020, 8, e001806.		110
10	Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncology, The, 2019, 20, 1083-1097.	10.7	611
11	A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151). Translational Oncology, 2019, 12, 828-835.	3.7	90
12	Real-world experience with pembrolizumab in patients with advanced melanoma. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.0	26
13	Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices. Future Oncology, 2019, 15, 459-471.	2.4	27
14	Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatric Blood and Cancer, 2018, 65, e27023.	1.5	31
15	Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2018, 36, 1668-1674.	1.6	360
16	Factors associated with immunotherapy selection in patients with advanced melanoma. Immunotherapy, 2018, 10, 1361-1369.	2.0	2
17	Impediment of Replication Forks by Long Non-coding RNA Provokes Chromosomal Rearrangements by Error-Prone Restart. Cell Reports, 2017, 21, 2223-2235.	6.4	13
18	Spontaneous regression of metastatic cancer: learning from neuroblastoma. Nature Reviews Cancer, 2014, 14, 71-72.	28.4	46

#	Article	IF	Citations
19	Comparison of Genome-Wide Binding of MyoD in Normal Human Myogenic Cells and Rhabdomyosarcomas Identifies Regional and Local Suppression of Promyogenic Transcription Factors. Molecular and Cellular Biology, 2013, 33, 773-784.	2.3	62
20	TERT hypermethylation: biomarker in paediatric brain tumours. Lancet Oncology, The, 2013, 14, 447-448.	10.7	7
21	Homology-mediated end-capping as a primary step of sister chromatid fusion in the breakage-fusion-bridge cycles. Nucleic Acids Research, 2013, 41, 9732-9740.	14.5	17
22	Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancer. Epigenetics, 2013, 8, 1254-1260.	2.7	16
23	Genome-wide DNA methylation studies suggest distinct DNA methylation patterns in pediatric embryonal and alveolar rhabdomyosarcomas. Epigenetics, 2012, 7, 400-408.	2.7	56
24	Assessment of palindromes as platforms for DNA amplification in breast cancer. Genome Research, 2012, 22, 232-245.	5.5	31
25	Genome-wide analysis of palindrome formation. Nature Genetics, 2010, 42, 279-279.	21.4	5
26	DNA methylation of developmental genes in pediatric medulloblastomas identified by denaturation analysis of methylation differences. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 234-239.	7.1	59
27	MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an arrested myoblast phase to a differentiated state. Genes and Development, 2009, 23, 694-707.	5.9	84
28	A duplication at chromosome 11q12.2-11q12.3 is associated with spinocerebellar ataxia type 20. Human Molecular Genetics, 2008, 17, 3847-3853.	2.9	50
29	EEL-1, a Hect E3 ubiquitin ligase, controls asymmetry and persistence of the SKN-1 transcription factor in the early C. elegans embryo. Development (Cambridge), 2007, 134, 2303-2314.	2.5	23
30	Reduced Dosage of pos-1 Suppresses Mex Mutants and Reveals Complex Interactions Among CCCH Zinc-Finger Proteins During Caenorhabditis elegans Embryogenesis. Genetics, 2006, 174, 1933-1945.	2.9	12
31	The function of a stem-loop in telomerase RNA is linked to the DNA repair protein Ku. Nature Genetics, 2001, 27, 64-67.	21.4	205
32	Exonuclease activity is required for sequence addition and Cdc13p loading at a de novo telomere. Current Biology, 2001, 11, 1336-1340.	3.9	136
33	All Things Must End: Telomere Dynamics in Yeast. Cold Spring Harbor Symposia on Quantitative Biology, 2000, 65, 281-296.	1.1	7
34	Telomerase-Mediated Telomere Addition In Vivo Requires DNA Primase and DNA Polymerases Î± and Î´. Cell, 1999, 99, 723-733.	28.9	351
35	Expression of neurotrophins and the low-affinity NGF receptor in septal and hippocampal reaggregate cultures: local physiologic effects of NGF synthesized in the septal region. Developmental Brain Research, 1992, 70, 123-133.	1.7	23